Kai Pharmaceuticals, Inc.

Gregory Bell

James E Tomlinson

Felix D Karim

Sarah Walter

The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.

Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders

Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.

Growing community of inventors

Tiburon, CA, United States of America

Gregory Bell